Predict your next investment

Corporation
HEALTHCARE | Drug Delivery
emisphere.com

See what CB Insights has to offer

Partners & Customers

10

Service Providers

1

About Emisphere Technologies

Emisphere Technologies operates as a commercial stage pharmaceutical and drug delivery firm in the United States.

Emisphere Technologies Headquarter Location

4 Becker Farm Road Suite 103

Roseland, New Jersey, 7068,

United States

973-532-8000

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Emisphere Technologies News

Microbial Therapeutic Products Market reach a valuation of US$ 30.55 Billion by the end of 2030

May 20, 2022

Search jobs 20-May-2022 Microbial Therapeutic Products Market reach a valuation of US$ 30.55 Billion by the end of 2030 Future Market Insights’ (FMI)  global microbial therapeutic products report  provides an exhaustive yet unbiased analysis of future growth projections, taking into account the aforementioned developments to provide a bird’s eye view of the landscape. According to the study, demand for microbial therapeutic products is likely to grow at a steady clip, driven chiefly by growing incidence of antimicrobial resistance. Over the years, the burden of antimicrobial resistance (AMR) has been escalating tremendously, besides prevalence of chronic conditions. The World Health Organization observes high resistance rates have been observed against antimicrobials used for treating urinary tract infections and certain types of diarrhea. For example, the rate of resistance to ciprofloxacin ranged anywhere between 8.4% and 93% across 33 countries. It is apprehended that this burden is compounding further due to the COVID-19 pandemic. Hence, efforts are underway to accelerate research for discovering breakthroughs in microbial therapeutics. Download FREE Sample Copy of Report:  https://www.futuremarketinsights.com/reports/sample/rep-gb-12891 Key Takeaways By product, anti-cancer agents to capture nearly 30% revenue by 2020-end, owing to prolific research breakthroughs By route of administration, injection pens to account for 2 out of 5 sales, attributed to patient hygiene concerns By source, bacteria based microbial therapeutic products to remain preferred Oncology to remain primary microbial therapeutic products application area, expanding at Y-o-Y rate exceeding 5% through 2020 Hospitals emerge as the primary microbial therapeutic end-users, attributed to availability of adequate infrastructure North America to remain the market hegemon, East Asia to be fastest growing market “Prominent manufacturers are seeking regulatory approvals to accelerate research and development operations for developing effective drug solutions to address the compounding antimicrobial resistance problems,” remarks the FMI analyst. Request a Complete TOC of this Report with figures:  https://www.futuremarketinsights.com/toc/rep-gb-12891 COVID-19 Impact Analysis The COVID-19 pandemic has adversely impact global economic outlook, with a prolonged recession on the cards across numerous industries. However, the microbial therapeutic products market has only stood to benefit from the pandemic crisis, as the global healthcare community accelerates efforts to find a potential cure for this deadly virus. With inoculation procedures already being initiated across the U.K., it is only a matter of time before the anti-COVID-19 vaccine is available on a global scale. Despite this availability, healthcare providers will have a long road ahead with respect to discovering an orally administered drug formulation. Therefore, governments are lending unconditional support to the global healthcare fraternity in terms of policy relaxation and disbursement of financial grants to aid in the research and development process, catapulting growth prospects. Competitive Landscape Prominent players operating in the global microbial therapeutic products market are emphasizing on acquiring regulatory approvals, forging partnerships and collaborations with competent authorities and biosimilars develop to capture substantial revenue shares across key regions. Some reputed players operating within the global microbial therapeutic products landscape include Dr. Reddy’s Laboratories, Pfizer Inc., Sanofi SA, Merck & Co. Inc., Novartis AG, Novo Nordisk A/S, Abbott Laboratories and Amgen Inc. to name a few. In November 2020, Dr. Reddy’s Laboratories announced a definitive agreement with Glenmark Pharmaceuticals Ltd. to acquire its anti-allergy brands Momat Rino, Momat Rino Advance and Momat A to market them across Russia, Kazakhstan and Uzbekistan respectively. In December 2020, Novo Nordisk announced the acquisition of Emisphere Technologies to exercise ownership of its Eligen SNAC oral delivery technology. The acquisition shall accelerate its GLP-1 receptor agonist seaglutide’s production on a larger scale. Feel free to ask your queries at  https://www.futuremarketinsights.com/ask-question/rep-gb-12891 More Valuable Insights on FMI’s Microbial Therapeutic Products Market Future Market Insights, in its new report, offers an unbiased analysis of the global microbial therapeutic products market, analyzing historical demand from 2015-2019 and forecast statistics for 2020-2030. The study reveals growth projections on the microbial therapeutic products market on the basis of product (growth factors, anti-cancer agents, immunosuppressants, enzymes & others), route of administration (single use pre-filled injection/injection pen, multi-use injectors & others), source (bacteria & fungi), application (metabolic disorders, haematological disorders, oncology, immunological disorders, infectious diseases, allergic diseases & others) and end-user (hospitals, pharmaceuticals & biopharmaceutical companies and research & academic institutions) across seven prominent regions. About FMI: Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years. Contact Us:

Emisphere Technologies Partners & Customers

10 Partners and customers

Emisphere Technologies has 10 strategic partners and customers. Emisphere Technologies recently partnered with Novo Nordisk on August 8, 2018.

Date

Type

Business Partner

Country

News Snippet

Sources

8/28/2018

Partner

Denmark

Emisphere’s Proprietary Eligen Technology Supports Novo Nordisk’s Oral Semaglutide

Novo Nordisk 's oral semaglutide utilizes Emisphere Technologies , Inc. 's proprietary Eligen ® Technology , and is subject to an exclusive license agreement that provides for payments by Novo Nordisk to Emisphere Technologies upon the achievement of specified development and sales milestones , in addition to royalty payments .

1

4/26/2018

Licensee

Denmark

Emisphere to Receive $7 Million Payment . Emisphere Amends License Agreement with Novo Nordisk.

Such statements are based on management 's current expectations , but actual results may differ materially due to various factors , including , but not limited to , the sufficiency of Emisphere Technologies , Inc. 's cash position , the success of our and our partner 's development and commercialization efforts , and our ability to successfully partner our Eligen ® Technology .

1

10/15/2015

Licensee

Denmark

Emisphere Signs License Agreement With Novo Nordisk to Develop Oral Formulations of Four Molecules Targeting Metabolic Indications and Amends GLP-1 Agreement

In conjunction with the signing of the new license agreement , Emisphere Technologies , Inc. and Novo Nordisk also amended their existing GLP-1 license agreement to provide for , among other things , a payment of $ 9.0 million to Emisphere Technologies , Inc. from Novo Nordisk as prepayment of a product development milestone in exchange for a reduction in future royalty payments .

5

2/20/2015

Licensee

Denmark

Subscribe to see more

Subscribe to see more

10

12/21/2010

Licensor

Denmark

Subscribe to see more

Subscribe to see more

10

Date

8/28/2018

4/26/2018

10/15/2015

2/20/2015

12/21/2010

Type

Partner

Licensee

Licensee

Licensee

Licensor

Business Partner

Country

Denmark

Denmark

Denmark

Denmark

Denmark

News Snippet

Emisphere’s Proprietary Eligen Technology Supports Novo Nordisk’s Oral Semaglutide

Novo Nordisk 's oral semaglutide utilizes Emisphere Technologies , Inc. 's proprietary Eligen ® Technology , and is subject to an exclusive license agreement that provides for payments by Novo Nordisk to Emisphere Technologies upon the achievement of specified development and sales milestones , in addition to royalty payments .

Emisphere to Receive $7 Million Payment . Emisphere Amends License Agreement with Novo Nordisk.

Such statements are based on management 's current expectations , but actual results may differ materially due to various factors , including , but not limited to , the sufficiency of Emisphere Technologies , Inc. 's cash position , the success of our and our partner 's development and commercialization efforts , and our ability to successfully partner our Eligen ® Technology .

Emisphere Signs License Agreement With Novo Nordisk to Develop Oral Formulations of Four Molecules Targeting Metabolic Indications and Amends GLP-1 Agreement

In conjunction with the signing of the new license agreement , Emisphere Technologies , Inc. and Novo Nordisk also amended their existing GLP-1 license agreement to provide for , among other things , a payment of $ 9.0 million to Emisphere Technologies , Inc. from Novo Nordisk as prepayment of a product development milestone in exchange for a reduction in future royalty payments .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

1

5

10

10

Emisphere Technologies Service Providers

1 Service Provider

Emisphere Technologies has 1 service provider relationship

Service Provider

Associated Rounds

Provider Type

Service Type

Merger

Investment Bank

Financial Advisor

Service Provider

Associated Rounds

Merger

Provider Type

Investment Bank

Service Type

Financial Advisor

Partnership data by VentureSource

Emisphere Technologies Team

2 Team Members

Emisphere Technologies has 2 team members, including former Chief Executive Officer, Chief Technology Officer, Lewis H Bender.

Name

Work History

Title

Status

Lewis H Bender

Chief Executive Officer, Chief Technology Officer

Former

Louis J. Paglia

UIL Holdings Corporation, Taha Investment Group, and Morgan Stanley & Co.

Chief Financial Officer

Former

Name

Lewis H Bender

Louis J. Paglia

Work History

UIL Holdings Corporation, Taha Investment Group, and Morgan Stanley & Co.

Title

Chief Executive Officer, Chief Technology Officer

Chief Financial Officer

Status

Former

Former

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.